CSL Ltd. and Talecris Biotherapeutics, Inc. have terminated the merger agreement announced on August 12, 2008, under which CSL agreed to acquire Talecris for $3.1 billion in cash. As part of terminating the agreement, CSL will pay Talecris a $75 million breakup fee. The plasma supply contract the parties entered into in connection with the merger agreement will remain in effect. Dr. Brian McNamee, chief executive officer and managing director of CSL, said, “We are disappointed that the ...